Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.45 |
| ▸ | CA2 | P00918 | 8/20 | 0.45 |
| ▸ | CA9 | Q16790 | 8/20 | 0.45 |
| ▸ | CA12 | O43570 | 7/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | PDIA4 | P13667 | 1/20 | 0.33 |
| ▸ | PDIA3 | P30101 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23552431 | 0.91 | CA12 (0.38) | CA1CA2CA9CA12 | |
| SCHEMBL23552378 | 0.79 | CYP2D6 (0.54) | CA1CA2CA12P4HBPDIA4 | |
| SCHEMBL23552395 | 0.79 | CYP2D6 (0.54) | CA1CA2CA12P4HBPDIA4 | |
| SCHEMBL25632099 | 0.79 | CYP2D6 (0.54) | CA1CA2CA12P4HBPDIA4 | |
| SCHEMBL25632653 | 0.75 | CA1 (0.43) | CA1CA2CA9CA12CA14 | |
| SCHEMBL2736530 | 0.74 | CA9 (0.60) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13464528 | 0.74 | CA9 (0.60) | CA1CA2CA9CA12CA14 | |
| SCHEMBL2723141 | 0.74 | CA9 (0.60) | CA1CA2CA9CA12CA14 | |
| SCHEMBL185606 | 0.74 | CA9 (0.60) | CA1CA2CA9CA12CA14 | |
| SCHEMBL7146506 | 0.74 | CA9 (0.60) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673909-B2 | Furaneone glycoside compound, pharmaceutical composition thereof, preparation method therefor, and application thereof | FUDAN UNIVERSITY (CN) | 2023-06-13 | — | — | US | disclosed |
| US-11673909-B2 | Furaneone glycoside compound, pharmaceutical composition thereof, preparation method therefor, and application thereof | FUDAN UNIVERSITY (CN) | 2023-06-13 | — | — | US | disclosed |
| WO-2021121362-A1 | FURANEOL GLYCOSIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 复旦大学 | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673909-B2 | Furaneone glycoside compound, pharmaceutical composition thereof, preparation method therefor, and application thereof | FAR1, CYP4A11, SFRP1 | CA1 777/4885CA2 2637/4885CA9 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.